Separating host and microbiome contributions to drug pharmacokinetics and toxicity

Science

Volumn 363, Issue 6427, 2019, Pages

  Zimmermann, Michael ^a   Zimmermann Kogadeeva, Maria ^a   Wegmann, Rebekka ^a,b   Goodman, Andrew L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; CLONAZEPAM; FLUOROURACIL; SORIVUDINE; BROXURIDINE;

ANTIMICROBIAL ACTIVITY; BIOAVAILABILITY; BIOTRANSFORMATION; DRUG; GENETICS; METABOLISM; METABOLITE; MICROORGANISM; TOXICITY;

ARTICLE; BACTERIUM CULTURE; BACTEROIDES THETAIOTAOMICRON; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; ENZYME ASSAY; EXPOSURE; GENE PRODUCT; GNOTOBIOTICS; HOST MICROBE INTERACTION; HUMAN; IN VIVO STUDY; INTESTINE FLORA; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MICROBIAL COMMUNITY; MICROBIOME; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TRANSPOSON; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; BIOTRANSFORMATION; ENZYMOLOGY; GENETICS; GERMFREE ANIMAL; MOUSE;

MUS;

ANIMALS; BACTEROIDES THETAIOTAOMICRON; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; BROMODEOXYURIDINE; CLONAZEPAM; GASTROINTESTINAL MICROBIOME; GERM-FREE LIFE; MICE;

EID: 85061193510     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aat9931     Document Type: Article

References (19)

1. A. Dahan, J. M. Miller, G. L. Amidon, Prediction of solubility and permeability class membership: Provisional BCS classification of the world’s top oral drugs. AAPS J. 11, 740–746 (2009). doi: 10.1208/s12248-009-9144-x; pmid: 19876745
2. R. Sender, S. Fuchs, R. Milo, Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLOS Biol. 14, e1002533 (2016). doi: 10.1371/journal.pbio.1002533; pmid: 27541692
3. T. Nishiyama et al., Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl) uracil in the presence of NADPH. Mol. Pharmacol. 57, 899–905 (2000). pmid: 10779372
4. C. Desgranges et al., Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res. 46, 1094–1101 (1986). pmid: 3943086
5. A. B. Van Kuilenburg et al., Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum. Genet. 104, 1–9 (1999). doi: 10.1007/PL00008711; pmid: 10071185
6. Human Microbiome Project Consortium, Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012). doi: 10.1038/nature11234; pmid: 22699609
7. H. Nakayama et al., Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics 7, 35–43 (1997). doi: 10.1097/00008571-199702000-00005; pmid: 9110360
8. A. L. Goodman et al., Identifying genetic determinants needed to establish a human gut symbiont in its habitat. Cell Host Microbe 6, 279–289 (2009). doi: 10.1016/j.chom.2009.08.003; pmid: 19748469
9. K. F. Jensen, P. Nygaard, Purine nucleoside phosphorylase from Escherichia coli and Salmonella typhimurium. Purification and some properties. Eur. J. Biochem. 51, 253–265 (1975). pmid: 235429
10. G. Z. Ferl, F.-P. Theil, H. Wong, Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: A mini-review on fundamental concepts and applications. Biopharm. Drug Dispos. 37, 75–92 (2016). doi: 10.1002/bdd.1994; pmid: 26461173
11. G. W. Elmer, R. P. Remmel, Role of the intestinal microflora in clonazepam metabolism in the rat. Xenobiotica 14, 829–840 (1984). doi: 10.3109/00498258409151481; pmid: 6506755
12. S. Takeno, T. Sakai, Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction. Teratology 44, 209–214 (1991). doi: 10.1002/tera.1420440209; pmid: 1925980
13. C. E. Cowles, N. N. Nichols, C. S. Harwood, BenR, a XylS homologue, regulates three different pathways of aromatic acid degradation in Pseudomonas putida. J. Bacteriol. 182, 6339–6346 (2000). doi: 10.1128/JB.182.22.6339-6346.2000; pmid: 11053377
14. L. V. Holdeman, in Anaerobe Laboratory Manual, L. V. Holdeman, W. E. C. Moore, E. P. Cato, Eds. (Anaerobe Laboratory, Virginia Polytechnic Institute and State University, Blacksburg, VA, ed. 4, 1977).
15. A. L. Goodman et al., Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice. Proc. Natl. Acad. Sci. U.S.A. 108, 6252–6257 (2011). doi: 10.1073/pnas.1102938108; pmid: 21436049
16. N. M. Koropatkin, E. C. Martens, J. I. Gordon, T. J. Smith, Starch catabolism by a prominent human gut symbiont is directed by the recognition of amylose helices. Structure 16, 1105–1115 (2008). doi: 10.1016/j.str.2008.03.017; pmid: 18611383
17. H. Machida et al., Deglycosylation of antiherpesviral 5-substituted arabinosyluracil derivatives by rat liver extract and enterobacteria cells. Biochem. Pharmacol. 49, 763–766 (1995). doi: 10.1016/0006-2952(94)00543-U; pmid: 7702634
18. B. Lim, M. Zimmermann, N. A. Barry, A. L. Goodman, Engineered Regulatory Systems Modulate Gene Expression of Human Commensals in the Gut. Cell 169, 547–558.e15 (2017). doi: 10.1016/j.cell.2017.03.045; pmid: 28431252
19. M. Zimmermann, M. Zimmermann-Kogadeeva, R. Wegmann, A. L. Goodman, PBPK_host-microbiome_model: Basic model release v2.1, Zenodo (2018); doi: 10.5281/zenodo.2548966